These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 25514064)

  • 41. The Role of Levomilnacipran in the Management of Major Depressive Disorder: A Comprehensive Review.
    Bruno A; Morabito P; Spina E; Muscatello MR
    Curr Neuropharmacol; 2016; 14(2):191-9. PubMed ID: 26572745
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A study of the effects of LY2216684, a selective norepinephrine reuptake inhibitor, in the treatment of major depression.
    Dubé S; Dellva MA; Jones M; Kielbasa W; Padich R; Saha A; Rao P
    J Psychiatr Res; 2010 Apr; 44(6):356-63. PubMed ID: 19909980
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Safety of Flibanserin in Women Treated With Antidepressants: A Randomized, Placebo-Controlled Study.
    Clayton AH; Croft HA; Yuan J; Brown L; Kissling R
    J Sex Med; 2018 Jan; 15(1):43-51. PubMed ID: 29289374
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Randomized, Double-Blind, Placebo-Controlled Trial of the mGlu2/3 Negative Allosteric Modulator Decoglurant in Partially Refractory Major Depressive Disorder.
    Umbricht D; Niggli M; Sanwald-Ducray P; Deptula D; Moore R; Grünbauer W; Boak L; Fontoura P
    J Clin Psychiatry; 2020 Jul; 81(4):. PubMed ID: 32663909
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A randomized, double-blind, duloxetine-referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD.
    Mahableshwarkar AR; Jacobsen PL; Chen Y; Serenko M; Trivedi MH
    Psychopharmacology (Berl); 2015 Jun; 232(12):2061-70. PubMed ID: 25575488
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with major depressive disorder: a preliminary double-blind, placebo-controlled study.
    DeBattista C; Doghramji K; Menza MA; Rosenthal MH; Fieve RR;
    J Clin Psychiatry; 2003 Sep; 64(9):1057-64. PubMed ID: 14628981
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Long-term management of major depressive disorder: are differences among antidepressant treatments meaningful?
    Shelton CI
    J Clin Psychiatry; 2004; 65 Suppl 17():29-33. PubMed ID: 15600379
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin-noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine.
    Montgomery SA; Nielsen RZ; Poulsen LH; Häggström L
    Hum Psychopharmacol; 2014 Sep; 29(5):470-82. PubMed ID: 25087600
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A randomized, double-blind placebo-controlled trial of oral creatine monohydrate augmentation for enhanced response to a selective serotonin reuptake inhibitor in women with major depressive disorder.
    Lyoo IK; Yoon S; Kim TS; Hwang J; Kim JE; Won W; Bae S; Renshaw PF
    Am J Psychiatry; 2012 Sep; 169(9):937-945. PubMed ID: 22864465
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy and tolerability of vortioxetine versus agomelatine, categorized by previous treatment, in patients with major depressive disorder switched after an inadequate response.
    Papakostas GI; Nielsen RZ; Dragheim M; Tonnoir B
    J Psychiatr Res; 2018 Jun; 101():72-79. PubMed ID: 29554497
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Reboxetine adjunct for partial or nonresponders to antidepressant treatment.
    Rubio G; San L; López-Muñoz F; Alamo C
    J Affect Disord; 2004 Jul; 81(1):67-72. PubMed ID: 15183602
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The impact of chronic depression on acute and long-term outcomes in a randomized trial comparing selective serotonin reuptake inhibitor monotherapy versus each of 2 different antidepressant medication combinations.
    Sung SC; Haley CL; Wisniewski SR; Fava M; Nierenberg AA; Warden D; Morris DW; Kurian BT; Trivedi MH; Rush AJ;
    J Clin Psychiatry; 2012 Jul; 73(7):967-76. PubMed ID: 22687487
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Modafinil augmentation of SSRI therapy in patients with major depressive disorder and excessive sleepiness and fatigue: a 12-week, open-label, extension study.
    Thase ME; Fava M; DeBattista C; Arora S; Hughes RJ
    CNS Spectr; 2006 Feb; 11(2):93-102. PubMed ID: 16520686
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder.
    Brannan SK; Mallinckrodt CH; Brown EB; Wohlreich MM; Watkin JG; Schatzberg AF
    J Psychiatr Res; 2005 Jan; 39(1):43-53. PubMed ID: 15504423
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Drop-out rates in placebo-controlled trials of antidepressant drugs: A systematic review and meta-analysis based on clinical study reports.
    Sharma T; Guski LS; Freund N; Meng DM; Gøtzsche PC
    Int J Risk Saf Med; 2019; 30(4):217-232. PubMed ID: 31561390
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial.
    Clauw DJ; Mease P; Palmer RH; Gendreau RM; Wang Y
    Clin Ther; 2008 Nov; 30(11):1988-2004. PubMed ID: 19108787
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness.
    Fava M; Thase ME; DeBattista C
    J Clin Psychiatry; 2005 Jan; 66(1):85-93. PubMed ID: 15669893
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Antidepressant class, age, and the risk of deliberate self-harm: a propensity score matched cohort study of SSRI and SNRI users in the USA.
    Miller M; Pate V; Swanson SA; Azrael D; White A; Stürmer T
    CNS Drugs; 2014 Jan; 28(1):79-88. PubMed ID: 24146116
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Vortioxetine: a New Treatment for Major Depressive Disorder.
    Connolly KR; Thase ME
    Expert Opin Pharmacother; 2016; 17(3):421-31. PubMed ID: 26679430
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Most antidepressant drugs are safe for patients with epilepsy at therapeutic doses: A review of the evidence.
    Kanner AM
    Epilepsy Behav; 2016 Aug; 61():282-286. PubMed ID: 27236241
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.